Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Author:

Abou-Alfa Ghassan K.12,Lau George3,Kudo Masatoshi4,Chan Stephen L.5,Kelley Robin Kate6,Furuse Junji7,Sukeepaisarnjaroen Wattana8,Kang Yoon-Koo9,Van Dao Tu10,De Toni Enrico N.11,Rimassa Lorenza1213,Breder Valeriy14,Vasilyev Alexander15,Heurgué Alexandra16,Tam Vincent C.17,Mody Kabir18,Thungappa Satheesh Chiradoni19,Ostapenko Yuriy20,Yau Thomas21,Azevedo Sergio22,Varela María23,Cheng Ann-Lii24,Qin Shukui25,Galle Peter R.26,Ali Sajid27,Marcovitz Michelle27,Makowsky Mallory27,He Philip27,Kurland John F.27,Negro Alejandra27,Sangro Bruno28

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

2. Weill Medical College, Cornell University, New York

3. Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong Special Administrative Region, China

4. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan

5. State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China

6. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

7. Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan

8. Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand

9. Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

10. Cancer Research and Clinical Trials Center, Department of Optimal Therapy, National Cancer Hospital, Hanoi, Vietnam

11. Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich, Germany

12. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan

13. Humanitas Cancer Center, Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano, Milan

14. Chemotherapy Department No. 17, N.N. Blokhin Russian Cancer Research Center, Moscow

15. Department of Oncology, Railway Clinical Hospital, St. Petersburg, Russia

16. Department of Hepato-Gastroenterology, Robert-Debré Hospital, Reims, France

17. Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada

18. Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL

19. Sri Venkateshwara Hospital, Bangalore, India

20. Department of Minimally Invasive and Endoscopic Surgery, Interventional Radiology, National Cancer Institute, Kiev, Ukraine

21. Queen Mary Hospital, Pok Fu Lam, Hong Kong Special Administrative Region, China

22. Unidade de Pesquisa em Oncologia Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

23. Liver Unit, Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias–Obra Social Cajastur, Instituto de Investigación Sanitaria del Principado de Asturias, Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturia, Oviedo, Spain

24. National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan

25. People’s Liberation Army Cancer Center, Nanjing Bayi Hospital, Nanjing, China

26. University Medical Center, Mainz, Germany

27. AstraZeneca, Gaithersburg, MD

28. Liver Unit and Hepato-pancreato-Biliary Oncology Area, Clínica Universidad de Navarra and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Pamplona, Spain

Publisher

Massachusetts Medical Society

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3